Breakthrough Alzheimer Drug Slows Cognitive Decline by 45%

A new biologic therapy targeting tau protein tangles has shown remarkable results in phase 3 trials, offering hope to the 55 million people worldwide living with Alzheimer's. This is an extended version of the article with additional details. The development marks a significant milestone in global affairs and has drawn widespread attention from experts and policymakers around the world.